Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. DAL
9. TMUS
10. VZ

Go back to Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c

Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results

July 27, 2016 4:01 PM EDT

WASHINGTON, July 27, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30, 2016.

"Vanda's commercial business continues to demonstrate strong progress and growth," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "We look forward to our planned launch of HETLIOZ in Germany in the third quarter and the opportunity to bring an important therapy to Non-24 patients in Europe."

Key Highlights:

Total net product sales from HETLIOZ® and Fanapt® were $36.0 million during the second... More